{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T00:55:03Z","timestamp":1775868903460,"version":"3.50.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T00:00:00Z","timestamp":1687564800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004435","name":"Universidad de Navarra","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004435","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Cardiovasc Imaging"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Owing to its pharmacodynamics and posology, the use of regadenoson for stress cardiac magnetic resonance (CMR) has potential advantages over other vasodilators. We sought to evaluate the safety, hemodynamic response and diagnostic performance of regadenoson stress-CMR in routine clinical practice. All regadenoson stress-CMR examinations performed between May 2017 and July 2020 at our institution were retrospectively reviewed. A total of 698 studies were included for the final analysis. A conventional stress\/rest protocol was performed using a 1.5T MRI scanner (Magnetom Aera, Siemens Healthineers, Erlangen, Germany). Adverse events, clinical symptoms, and hemodynamic response were assessed. Diagnostic accuracy of the test was evaluated in patients who underwent invasive coronary angiography. Nearly half of patients (48.5%) remained asymptomatic. Most common clinical symptoms included dyspnea (137, 19.6%), chest pain (116, 16.6%) and flushing (44, 6.3%). Two patients (0.28%) could not complete the examination due to severe hypotension or unbearable chest pain. Overall, an increase in heart rate (HR) response (36.2% [IQR: 22.5?50.9]) and a decrease in systolic and diastolic blood pressure (BP) (median systolic BP response of -5% [IQR: -11.5-0.6]; median diastolic BP response of -6.3 mmHg [IQR: -13.4-0]) was observed. Patients with symptoms induced by regadenoson showed higher HR response (40.3%, IQR: 26.4?56.1 vs. 32.4%, IQR: 19-45.6, p\u2009&lt;\u20090.001), whereas a blunted HR response was observed in diabetic (29.6%, IQR: 18.4?42 p\u2009&lt;\u20090.001), obese (31.7%, IQR: 20.7?46.2 p\u2009=\u20090.005) and patients aged 70 years or older (32.9%, IQR: 22.6?43.1 p\u2009&lt;\u20090.001). Overall, regadenoson stress-CMR showed 95.65% (IQ 91.49?99.81) sensitivity, 54.84% (IQ 35.71?73.97) specificity, 86.99% (IQ 82.74?94.68) positive predictive value, and 77.27% (IQ 57.49?97.06) negative predictive value for detecting significant coronary stenosis as compared with invasive coronary angiography. Regadenoson is a well-tolerated vasodilator that can be safely employed for stress perfusion CMR, with high diagnostic performance.<\/jats:p>","DOI":"10.1007\/s10554-023-02877-z","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T11:46:34Z","timestamp":1687607194000},"page":"1765-1774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, feasibility, and hemodynamic response of regadenoson for stress perfusion CMR"],"prefix":"10.1007","volume":"39","author":[{"given":"Javier","family":"Mu\u00f1iz-S\u00e1enz-Diez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Ezponda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meylin","family":"Caballeros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"de la Fuente","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan J.","family":"Gavira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorka","family":"Bastarrika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,24]]},"reference":[{"issue":"3","key":"2877_CR1","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1093\/eurheartj\/ehz660","volume":"41","author":"E Sorbets","year":"2020","unstructured":"Sorbets E, Fox KM, Elbez Y, Danchin N, Dorian P, Ferrari R et al (2020) Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. Eur Heart J 41(3):347\u2013355. https:\/\/doi.org\/10.1093\/eurheartj\/ehz660","journal-title":"Eur Heart J"},{"key":"2877_CR2","doi-asserted-by":"publisher","unstructured":"Knuuti J, Wijns W, Chairperson I, Capodanno D, France CF, Denmark EP et al (2020) 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes the Task Force for the diagnosis and management of chronic. 407\u2013477. https:\/\/doi.org\/10.1093\/eurheartj\/ehz425","DOI":"10.1093\/eurheartj\/ehz425"},{"issue":"14","key":"2877_CR3","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1016\/j.jacc.2007.06.030","volume":"50","author":"KR Nandalur","year":"2007","unstructured":"Nandalur KR, Dwamena BA, Choudhri AF, Nandalur MR, Carlos RC (2007) Diagnostic performance of stress Cardiac magnetic resonance imaging in the detection of coronary artery disease. A Meta-analysis. J Am Coll Cardiol 50(14):1343\u20131353. https:\/\/doi.org\/10.1016\/j.jacc.2007.06.030","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"2877_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1532-429X-12-295","volume":"56","author":"MM Hamon","year":"2010","unstructured":"Hamon MM, Fau G, N\u00e9e G, Ehtisham J, Morello R et al (2010) Meta-analysis of the diagnostic performance of stress perfusion cardiovascular magnetic resonance for detection of coronary artery disease. J Cardiovasc Magn Reson 56(12):29. https:\/\/doi.org\/10.1186\/1532-429X-12-295","journal-title":"J Cardiovasc Magn Reson"},{"issue":"13","key":"2877_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/eurheartj\/ehw095","volume":"38","author":"I Danad","year":"2017","unstructured":"Danad I, Szymonifka J, Twisk JWR, Norgaard BL, Zarins CK, Knaapen P et al (2017) Diagnostic performance of cardiac imaging methods to diagnose ischaemia-causing coronary artery disease when directly compared with fractional flow reserve as a reference standard: a meta-analysis. Eur Heart J 38(13):991\u2013998. https:\/\/doi.org\/10.1093\/eurheartj\/ehw095","journal-title":"Eur Heart J"},{"key":"2877_CR6","doi-asserted-by":"publisher","unstructured":"Menadas JVM, Lopez-lereu MP, Erill JE, Gonzalez AM, Gonzalez PG (2016) Pharmacological stress cardiovascular magnetic resonance: feasibility and safety in a large multicentre prospective registry. 308\u2013315. https:\/\/doi.org\/10.1093\/ehjci\/jev153","DOI":"10.1093\/ehjci\/jev153"},{"key":"2877_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s10554-018-1494-y","author":"A Garc\u00eda-Baiz\u00e1n","year":"2018","unstructured":"Garc\u00eda-Baiz\u00e1n A, Millor M, Bartolome P, Ezponda A, Pueyo J, Gavira JJ, Bastarrika G (2018) Adenosine triphosphate (ATP) and adenosine cause similar vasodilator effect in patients undergoing stress perfusion cardiac magnetic resonance imaging. Int J Cardiovasc Imaging. https:\/\/doi.org\/10.1007\/s10554-018-1494-y","journal-title":"Int J Cardiovasc Imaging"},{"key":"2877_CR8","doi-asserted-by":"publisher","unstructured":"Iskandrian AE, Bateman TM, Belardinelli L, Blackburn B, Cerqueira MD, Hendel RC et al (2007) Adenosine versus regadenoson comparative evaluation in myocardial perfusion imaging: results of the ADVANCE phase 3 multicenter international trial. 645\u2013658. https:\/\/doi.org\/10.1016\/j.nuclcard.2007.06.114","DOI":"10.1016\/j.nuclcard.2007.06.114"},{"key":"2877_CR9","doi-asserted-by":"publisher","unstructured":"Mahmarian JJ, Peterson LE, Xu J, Cerqueira MD, Iskandrian AE, Bateman TM et al (2014) Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials. 22(2):248\u2013261. https:\/\/doi.org\/10.1007\/s12350-014-9981-6","DOI":"10.1007\/s12350-014-9981-6"},{"key":"2877_CR10","doi-asserted-by":"publisher","unstructured":"Vasu S, Bandettini WP, Hsu L, Kellman P, Leung S, Mancini C et al (2013) Regadenoson and adenosine are equivalent vasodilators and are superior than dipyridamole- a study of first pass quantitative perfusion cardiovascular magnetic resonance. https:\/\/doi.org\/10.1186\/1532-429X-15-85. 15;85","DOI":"10.1186\/1532-429X-15-85"},{"issue":"8","key":"2877_CR11","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/j.jcmg.2009.04.011","volume":"2","author":"TM Bateman","year":"2009","unstructured":"Bateman TM, Thomas GS, Hendel RC, Moye LA, Olmsted AW (2009) Regadenoson induces comparable left ventricular perfusion defects as Adenosine. JCMG 2(8):959\u2013968. https:\/\/doi.org\/10.1016\/j.jcmg.2009.04.011","journal-title":"JCMG"},{"key":"2877_CR12","doi-asserted-by":"crossref","unstructured":"Doukky R (2014) Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge. ;129\u201337","DOI":"10.2147\/COPD.S56879"},{"key":"2877_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1007\/s12350-012-9547-4","volume":"19","author":"BM Prenner","year":"2012","unstructured":"Prenner BM, Bukofzer S, Int M, Behm S, Feaheny K, Mcnutt BE (2012) Study assessing the safety and tolerability of regadenoson in subjects with asthma or chronic obstructive pulmonary disease. J Nucl Cardiol 19:681\u2013692. https:\/\/doi.org\/10.1007\/s12350-012-9547-4","journal-title":"J Nucl Cardiol"},{"issue":"3","key":"2877_CR14","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.nuclcard.2008.02.013","volume":"15","author":"GS Thomas","year":"2008","unstructured":"Thomas GS, Tammelin BR, Schiffman GL, Marquez R, Rice DL, Milikien D et al (2008) Safety of regadenoson, a selective adenosine A2A agonist, in patients with chronic obstructive pulmonary disease: a randomized, double-blind, placebo-controlled trial (RegCOPD trial). J Nucl Cardiol 15(3):319\u2013328. https:\/\/doi.org\/10.1016\/j.nuclcard.2008.02.013","journal-title":"J Nucl Cardiol"},{"key":"2877_CR15","doi-asserted-by":"publisher","unstructured":"Gabriella Vincenti MD, Masci abPGiorgio (2017) MD, PHD, a, b Pierre Monney, MD, a, b Tobias Rutz, MD, a, b Sarah Hugelshofer, MD, a Mirdita Gaxherri, MD, a Olivier Muller, MD, PHD, a Juan F. Iglesias, MD, a Eric Eeckhout, MD, PHD, a Valentina Lorenzoni, B. Stress Perfusion CMR in Patients With Known and Suspected CAD. J A C C C a r d i o v a s c u l a r I m a g i n g. ;10(5). https:\/\/doi.org\/10.1016\/j.jcmg.2017.02.006","DOI":"10.1016\/j.jcmg.2017.02.006"},{"key":"2877_CR16","doi-asserted-by":"publisher","unstructured":"Lipinski MJ, Mcvey CM, Berger JS, Kramer CM, Salerno M (2013) Prognostic value of stress Cardiac magnetic resonance imaging in patients with known or suspected coronary artery disease a systematic review and Meta-analysis. JACC 62(9). https:\/\/doi.org\/10.1016\/j.jacc.2013.03.080","DOI":"10.1016\/j.jacc.2013.03.080"},{"key":"2877_CR17","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s00392-006-0410-y","volume":"467","author":"P Bernhardt","year":"2006","unstructured":"Bernhardt P, Levenson B (2006) Contrast-enhanced adenosine-stress magnetic resonance imaging feasibility and practicability of a protocol for detection or exclusion of ischemic heart disease in an outpatient setting. Clin Res Cardiol 467:461\u2013467. https:\/\/doi.org\/10.1007\/s00392-006-0410-y","journal-title":"Clin Res Cardiol"},{"issue":"October","key":"2877_CR18","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1259\/bjr\/14829242","volume":"85","author":"JP Khoo","year":"2012","unstructured":"Khoo JP, Grundy BJ, Steadman CD (2012) Stress cardiovascular MR in routine clinical practice: referral patterns, accuracy, tolerance, safety and incidental findings. Br J Radiol 85(October):851\u2013857. https:\/\/doi.org\/10.1259\/bjr\/14829242","journal-title":"Br J Radiol"},{"issue":"3","key":"2877_CR19","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.rec.2019.02.007","volume":"73","author":"A Esteban-Fern\u00e1ndez","year":"2019","unstructured":"Esteban-Fern\u00e1ndez A, Bastarrika G, Castanon E, Coma-Canella I, Barba-Cosials J, Jim\u00e9nez-Mart\u00edn M et al (2019) Prognostic role of stress cardiac magnetic resonance in the elderly. Rev Espa\u00f1ola Cardiol 73(3):241\u2013247. https:\/\/doi.org\/10.1016\/j.rec.2019.02.007","journal-title":"Rev Espa\u00f1ola Cardiol"},{"issue":"3","key":"2877_CR20","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1007\/s10554-008-9392-3","volume":"25","author":"TD Karamitsos","year":"2009","unstructured":"Karamitsos TD, Arnold JR, Pegg TJ, Cheng ASH, van Gaal WJ, Francis JM et al (2009) Tolerance and safety of adenosine stress perfusion cardiovascular magnetic resonance imaging in patients with severe coronary artery disease. Int J Cardiovasc Imaging 25(3):277\u2013283. https:\/\/doi.org\/10.1007\/s10554-008-9392-3","journal-title":"Int J Cardiovasc Imaging"},{"issue":"1","key":"2877_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1186\/1532-429X-12-66","volume":"12","author":"TD Karamitsos","year":"2010","unstructured":"Karamitsos TD, Ntusi NA, Francis JM, Holloway CJ, Myerson SG, Neubauer S (2010) Feasibility and safety of high-dose adenosine perfusion cardiovascular magnetic resonance. J Cardiovasc Magn Reson 12(1):66. https:\/\/doi.org\/10.1186\/1532-429X-12-66","journal-title":"J Cardiovasc Magn Reson"},{"key":"2877_CR22","doi-asserted-by":"publisher","unstructured":"Tejani FH, Thompson RC, Kristy R, Bukofzer S (2014) Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: a prospective, randomized, multicenter study. 979\u2013989. https:\/\/doi.org\/10.1007\/s10554-014-0419-7","DOI":"10.1007\/s10554-014-0419-7"},{"issue":"11","key":"2877_CR23","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1007\/s10554-017-1157-4","volume":"33","author":"R Van Dijk","year":"2017","unstructured":"Van Dijk R, Kuijpers D, Dijkman TAMKPRM, Van (2017) Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine- induced hyperemia as measured by T1 mapping. Int J Cardiovasc Imaging 33(11):1753\u20131759. https:\/\/doi.org\/10.1007\/s10554-017-1157-4","journal-title":"Int J Cardiovasc Imaging"},{"issue":"3","key":"2877_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.rx.2019.11.002","volume":"62","author":"G Bastarrika","year":"2020","unstructured":"Bastarrika G, Ezponda A, Garc\u00eda Baizan A, Calvo M, Pueyo JC, Gavira JJ et al (2020) Safety of regadenoson for vasodilation in cardiac MRI stress tests. Radiol 62(3):213\u2013221. https:\/\/doi.org\/10.1016\/j.rx.2019.11.002","journal-title":"Radiol"},{"key":"2877_CR25","doi-asserted-by":"publisher","unstructured":"Hundley WG, Bluemke D, Bogaert JG, Friedrich MG, Higgins CB, Lawson MA et al (2009 Mar) Society for Cardiovascular magnetic resonance guidelines for reporting cardiovascular magnetic resonance examinations. J Cardiovasc Magn Reson 11:5. https:\/\/doi.org\/10.1186\/1532-429X-11-5","DOI":"10.1186\/1532-429X-11-5"},{"issue":"4","key":"2877_CR26","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.ahj.2009.01.011","volume":"157","author":"FG Hage","year":"2009","unstructured":"Hage FG, Heo J, Franks B, Belardinelli L, Blackburn B (2009) Differences in heart rate response to adenosine and regadenoson in patients with and without diabetes mellitus. Am Heart J 157(4):771\u2013776. https:\/\/doi.org\/10.1016\/j.ahj.2009.01.011","journal-title":"Am Heart J"},{"issue":"10","key":"2877_CR27","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/eurheartj\/ehs022","volume":"34","author":"J Schwitter","year":"2013","unstructured":"Schwitter J, Wacker CM, Wilke N, Al-Saadi N, Sauer E, Huettle K et al (2013) MR-IMPACT II: magnetic resonance imaging for myocardial perfusion assessment in coronary artery disease trial: perfusion-cardiac magnetic resonance vs. single-photon emission computed tomography for the detection of coronary artery disease: a comparative. Eur Heart J 34(10):775\u2013781. https:\/\/doi.org\/10.1093\/eurheartj\/ehs022","journal-title":"Eur Heart J"},{"issue":"7","key":"2877_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1093\/ehjci\/jet27","volume":"15","author":"KL Nguyen","year":"2014","unstructured":"Nguyen KL, Bandettini WP, Shanbhag S, Leung SW, Wilson JR, Arai AE (2014) Safety and tolerability of regadenoson CMR. Eur Heart J Cardiovasc Imaging 15(7):753\u2013760. https:\/\/doi.org\/10.1093\/ehjci\/jet27","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"1","key":"2877_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s10554-021-02363-4","volume":"38","author":"JV Monmeneu Menadas","year":"2022","unstructured":"Monmeneu Menadas JV, Garc\u00eda Gonzalez MP, Lopez-Lereu MP, Higueras Ortega L, Maceira Gonzalez AM (2022) Safety and tolerability of regadenoson in comparison with adenosine stress cardiovascular magnetic resonance: data from a multicentre prospective registry. Int J Cardiovasc Imaging 38(1):195\u2013209. https:\/\/doi.org\/10.1007\/s10554-021-02363-4","journal-title":"Int J Cardiovasc Imaging"},{"key":"2877_CR30","doi-asserted-by":"publisher","unstructured":"Reyes E, Staehr P, Olmsted A (2011) Effect of body mass index on the efficacy, side effect profile, and plasma concentration of fixed-dose regadenoson for myocardial perfusion imaging. 18:620\u2013627. https:\/\/doi.org\/10.1007\/s12350-011-9377-9","DOI":"10.1007\/s12350-011-9377-9"},{"issue":"3","key":"2877_CR31","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/j.jcmg.2008.02.003","volume":"1","author":"MD Cerqueira","year":"2008","unstructured":"Cerqueira MD, Nguyen P, Staehr P, Underwood SR, Iskandrian AE (2008) Effects of Age, gender, obesity, and diabetes on the efficacy and safety of the selective A2A agonist Regadenoson Versus Adenosine in Myocardial Perfusion Imaging. J A C C C a r d i o v a s c u l a r I m a g. i n g 1(3):307\u2013316. https:\/\/doi.org\/10.1016\/j.jcmg.2008.02.003","journal-title":"i n g"},{"key":"2877_CR32","doi-asserted-by":"crossref","unstructured":"Dibella EVR, Fluckiger JU, Chen L, Ho T, Pack NA, Matthews B et al (2012) The effect of obesity on regadenoson-induced myocardial hyperemia: a quantitative magnetic resonance imaging study. ;1435\u201344. doi10.1007\/s10554-011-9949-4","DOI":"10.1007\/s10554-011-9949-4"},{"issue":"6","key":"2877_CR33","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.amjcard.2009.11.042","volume":"105","author":"FG Hage","year":"2010","unstructured":"Hage FG, Perry G, Heo J, Iskandrian AE (2010) Blunting of the heart rate response to Adenosine and Regadenoson in Relation to Hyperglycemia and the metabolic syndrome. AJC 105(6):839\u2013843. https:\/\/doi.org\/10.1016\/j.amjcard.2009.11.042","journal-title":"AJC"},{"issue":"6","key":"2877_CR34","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s12350-011-9429-1","volume":"18","author":"FG Hage","year":"2011","unstructured":"Hage FG, Dean P, Iqbal F, Heo J, Iskandrian AE (2011) A blunted heart rate response to regadenoson is an independent prognostic indicator in patients undergoing myocardial perfusion imaging. J Nucl Cardiol 18(6):1086\u20131094. https:\/\/doi.org\/10.1007\/s12350-011-9429-1","journal-title":"J Nucl Cardiol"},{"key":"2877_CR35","doi-asserted-by":"publisher","unstructured":"Bhave NM, Freed BH, Yodwut C, Kolanczyk D, Dill K, Lang RM (2012) Considerations when measuring myocardial perfusion reserve by cardiovascular magnetic resonance using regadenoson. 1\u20138. https:\/\/doi.org\/10.1186\/1532-429X-14-89","DOI":"10.1186\/1532-429X-14-89"}],"container-title":["The International Journal of Cardiovascular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-023-02877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10554-023-02877-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10554-023-02877-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,25]],"date-time":"2023-09-25T20:35:42Z","timestamp":1695674142000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10554-023-02877-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,24]]},"references-count":35,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["2877"],"URL":"https:\/\/doi.org\/10.1007\/s10554-023-02877-z","relation":{},"ISSN":["1875-8312"],"issn-type":[{"value":"1875-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,24]]},"assertion":[{"value":"3 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose regarding this article. Gorka Bastarrika is speaker for General Electric and Siemens Healthineers, participates in educational activities for Bayer, General Electric and Siemens Healthineers and has received institutional research grants from Siemens Healthineers and Guerbet.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}